Immune checkpoints are regulators of the immune system, playing a key role in maintaining immune homeostasis and self-tolerance, and preventing autoimmune responses. Some cancers can “escape” the attack from the immune system by activating these immune checkpoints to suppress the nascent anti-tumor immune response.

There are two types of checkpoint molecules in the immune checkpoint signaling pathway: co-stimulatory checkpoints that activate the immune system, and co-inhibitory checkpoints that inhibit the activation of immune responses against tumor cells. Therapies targeting immune checkpoint proteins have become popular in anti-cancer drug development. Currently approved drugs include inhibitors of PD-1, PD-L1, and CTLA-4 to treat various cancer types, including melanoma, lung cancer, kidney cancer, and lymphoma.

EUPROTEIN offers the high-quality recombinant proteins for the development of novel therapies targeting immune checkpoint molecules. Explore our extensive collection by clicking the buttons below.